Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†

Kawai, Akira; Araki, Nobuhito; Naito, Yoichi; Ozaki, Toshifumi; Sugiura, Hideshi; Yazawa, Yasuo; Morioka, Hideo; Matsumine, Akihiko; Saitô, Kenichi; Asami, Shun; Isu, Kazuo

doi:10.1093/jjco/hyw175

Cited by 51 publications

(66 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another open-label, multicentre, and non-randomized Phase II trial evaluated patients with advanced or metastatic STS. This study found a median PFS and ORR for LPS/LMS patients of 5.5 and 17.0 months, respectively, against 2.0 months for both parameters in other subtypes (Kawai et al, 2017…”

Section: Clinical Evidencesmentioning

confidence: 54%

Enriching cancer pharmacology with drugs of marine origin

Jimenez¹,

Wilke

Branco

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Marine natural products have proven, over the last half-century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment-cytarabine (Cytosar-U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®), and plitidepsin (Aplidin®)-together with those in late clinical trial phases-lurbinectedin, plinabulin, marizomib, and plocabulin-the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy. 1 | INTRODUCTION Natural products have long been used in the treatment of human maladies and set a strong foundation upon which modern pharmacology has been erected. Particularly for cancer treatment, chemotherapeutic agents of natural origin have remarkably impacted the field, not only for their clinical importance but also for allowing the expansion of knowledge in cancer pharmacology. Natural agents like doxorubicin, paclitaxel, vincristine, and vinblastine are commonly used as first-line treatments for several cancers. The compounds of marine origin have a more recent history. Nevertheless, studies have shown their unique

show abstract

Section: Clinical Evidencesmentioning

confidence: 54%

Enriching cancer pharmacology with drugs of marine origin

Jimenez¹,

Wilke

Branco

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…More recently, clinical trials of eribulin for the treatment of soft‐tissue sarcoma have been reported . According to those clinical trials, eribulin was permitted for the treatment of soft‐tissue sarcoma, but not angiosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

et al. 2018

View full text Add to dashboard Cite

Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second-line therapy for advanced CAS remains contentious. This report describes three patients with advanced CAS treated with eribulin. In addition, we investigated serum soluble (s)CD163, chemokine (C-X-C motif) ligand 10 (CXCL10) and chemokine (C-C motif) ligand 2 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS.

show abstract

“…It may be used as therapy for metastatic breast cancer or metastatic/unresectable liposarcomas. A phase II study of eribulin in patients with previously treated late-stage or metastatic soft tissue sarcoma found pancyptopaenia and febrile neutropaenia to be the most common adverse effects 19. Additional side effects of eribulin include fatigue, alopecia, gastrointestinal manifestations, peripheral neuropathy and QT prolongation.…”

Section: Discussionmentioning

confidence: 99%

Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma

2018

View full text Add to dashboard Cite

A middle-aged woman with a history of leiomyosarcoma of the uterus treated with surgery and adjuvant chemotherapy suffered a bulky metastatic recurrence 1 year later. She elected treatment with palliative eribulin, presenting with acute renal failure and electrolyte abnormalities consistent with tumour lysis syndrome on cycle 1 day 8. Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital.

show abstract

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†

Abstract: This phase 2 study investigated eribulin in previously treated Japanese patients with advanced/metastatic soft tissue sarcoma. Eribulin showed clinical activity together with a manageable safety profile.

Cited by 51 publications

References 21 publications

Enriching cancer pharmacology with drugs of marine origin

Enriching cancer pharmacology with drugs of marine origin

Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma

Contact Info

Product

Resources

About